Blog by Alicia Gailliez, Business Development Manager, One Nucleus
You probably will not have read many blogs recently that start with a forest fire analogy, especially one targeted towards a Life Science audience, but here goes! On my recent trip to Yellowstone National Park, we learnt about the fires of 1988. Although devastating, the fires were an unprecedented chance to study the ecological impacts in an ecosystem and it was found that the environment would regenerate in a different way and one that could sustain a greater diversity of vegetation. This re-orientation can be…
Blog by Tony Jones, CEO, One Nucleus
January 2021 saw the launch of the One Nucleus Virtual Innovation Centre (VIC) created to provide a means for growing life science R&D companies to connect with and leverage the breadth of the One Nucleus ecosystem. A complementary offering to the variety of Innovation Centre, Accelerator and Incubator-style initiatives that are established and collated at a national level in the BIA Innovation Map, recognising that the need for support isn’t essentially time or set programme limited and requires those businesses to integrate into a coordinated…
Guest blog post by Chris Cooper, Scientific Specialist II, Immunotoxicology & Immunology, Labcorp Early Development Laboratories Ltd
In our previous post, we outlined the dangers of Cytokine Release Syndrome (CRS) and the importance of preclinical Cytokine Release Assays (CRAs) when developing monoclonal antibodies (mAbs) that interact with the patient’s immune system. In this second post, we describe the different kinds of assays in use and how these may fit into your drug development program. An alternative type of CRA, peripheral blood mononuclear cell (PBMC) blood…
Guest blog by Dave Mead, Director of Business Development, Isogenica Limited
I recently joined One Nucleus ’ BioWednesday panel to debate whether using Government R&D incentives are worth it.
So, are they? As a growing biotech company, Isogenica Limited has experience in accessing grant opportunities and other R&D incentives. Yet, for many start-ups, it can be a steep learning curve to work out what’s available and the best use of precious time and resources. Alongside panellists from Octane OC and EY, I collated the following useful…
Guest blog by Grace Gregory, Student, University of Manchester
I'm Grace and I am one of two students at the University of Manchester funded by NF2 BioSolutions UK. People with Neurofibromatosis Type 2 (NF2) often have many tumours that develop in the central nervous system along the spine and brain requiring risky surgeries over a lifetime with few alternatives.
The aim of my PhD is to investigate potential therapeutic avenues to reduce the number of surgeries needed and provide more treatment options to those with NF2.
I am currently looking at immune cells such as T…
1 in 4 people in England will experience a mental health problem of some kind each year (The Adult Psychiatric Morbidity Survey, 2007). The more we talk about mental health the more we break down the stigma and create a safe place for people to speak out about how they are feeling. Mental health problems can affect individuals very differently and be completely invisible to others.
Check in with your colleagues, family, and friends when you can and if you are struggling with your own mental health, I would encourage you to speak to someone close to you that you trust and remember that it is…
Tony Jones, CEO & Jasmin Bannister, Events & Communications Administrator - One Nucleus
“Good company in a journey makes the way seem shorter”
The above quote by English writer Izaak Walton could have been crafted for those deciding on where to develop their career in Life Sciences. The East of England’s standing as one of the premier innovation ecosystems in the world is rarely, if ever, questioned. Generating a long history of great minds assembling to address global challenges, the creation of new companies and the magnetic effect to established corporate and financial means…
Hanna Beaumont FIRM, Director, Science Technology, Partners&
Safety in the lab, working from home, employment law, contract disputes, Covid... company directors are now exposed to unprecedented liability for actions and decisions they make on behalf of their business. This means direct exposure of the personal assets of your board members and key decision makers – including NEDs.
Being a director or senior officer of a business comes with advantages – driving innovation and growth, creating a legacy, leading your people; but with great power comes great responsibility – and…
Tony Jones, Chief Executive Officer, One Nucleus
When it comes to change, there is often a feeling of apprehension among those that it might impact the most. Yet as Douglas Baldwin pointed out “Change is inevitable, change will always happen, but you have to apply direction to change and that’s when it’s progress’. Perhaps, just like the Borg in Star Trek claimed: “Resistance is futile!”. Accepting change will happen in all aspects of life, then the challenge becomes one of adding direction for the result to be progress as opposed to just different.
It is in the DNA of One Nucleus to embrace…
Tony Jones, Chief Executive Officer, One Nucleus
As always, it is a privileged part of the month where I get to be in contact with the One Nucleus network by welcoming you to our eNews.
There are a plethora of good news stories to choose from in the sector, many of which are posted by members to our website, LinkedIn and Twitter feeds where you can stay up to date. Below, I recap on some One Nucleus highlights from the last month and update you on some upcoming plans.
Do you feel supported in the UK?It would have been hard for anyone in the UK Life Sciences to have escaped the media…